The US Food and Drug Administration (FDA) has approved Genentech's giredestrant (Wilserdly) in combination with everolimus for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated locally advanced or metastatic breast cancer following specified prior endocrine therapy.
The approval covers patients whose disease recurred during or after endocrine-based adjuvant therapy or progressed on at least 1 endocrine-based regimen in the metastatic setting. The agency also authorized FoundationOne Liquid CDx as a companion diagnostic to identify eligible patients with ESR1 mutations.
Giredestrant is an oral estrogen receptor antagonist that blocks estrogen signaling and promotes receptor degradation, according to its label. The approval was supported by the phase 3 evERA Breast Cancer trial, which demonstrated significantly longer progression-free survival (PFS) with giredestrant plus everolimus than with physician's choice of endocrine therapy plus everolimus in patients with ESR1-mutated tumors.
According to the announcement, the randomized, open-label, multicenter trial enrolled 373 adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer, including 207 with ESR1 mutations. Patients received giredestrant 30 mg once daily or physician's choice of exemestane, fulvestrant, or tamoxifen, with both groups receiving everolimus 10 mg daily.
The primary endpoint was investigator-assessed PFS under Response Evaluation Criteria in Solid Tumors version 1.1. Among patients with ESR1-mutated tumors, median PFS was 10 months with giredestrant plus everolimus vs 5.5 months with comparator endocrine therapy plus everolimus, a statistically significant improvement. Objective response rates were 27% and 14%, respectively. Overall survival data remained immature at the time of the PFS analysis. The most common adverse reactions, reported in at least 20% of patients receiving giredestrant plus everolimus, included stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea.
The prescribing information includes warnings for bradycardia and embryo-fetal toxicity. Bradycardia occurred in 3.8% of patients receiving the combination in evERA, with all cases classified as asymptomatic. The label advises more frequent heart rate monitoring in patients with preexisting bradycardia or those taking medications that slow heart rate.
The recommended giredestrant dose is 30 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. The prescribing information also advises avoiding strong CYP3A inhibitors and inducers.
Sources:FDA, Genentech prescribing information
